Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LVGN7409 and LVGN3616 in Resectable HPV-negative HNSCC
NCT06159621Phase 1Active, not recruiting
- Sponsor
- University of Pennsylvania
- Start
- Jul 2024
- Primary completion
- Mar 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of LVGN7409 in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by University of Pennsylvania. Primary endpoints: T cell frequency pre-treatment compared to post-treatment at 1 year and Number of participants who undergo planned surgery within 6 weeks after drug administration. Started Jul 2024; status: active, not recruiting.
02
Drugs
LVGN7409
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06159621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06159621.